GW Pharmaceuticals (GWPH)

gwpharma-logoWhile the cannabis industry in the US has only recently found its big break, medical marijuana research and development has already been well underway for more than a decade now. The UK-based GW Pharmaceuticals, PLC is one of the companies that have been established in this field in the 1990s.

GW Pharmaceuticals is a biopharmaceutical company that focuses on developing cannabis medications, especially for pain management. Two of its biggest endeavors are on the drugs Sativex and Epidiolex.

Sativex is an indicated treatment for multiple sclerosis (MS) spasticity and for cancer pain. Its two principal components are the cannabis-derived substances cannabidiol (CBD) and delta-9 tetrahydrocannabinol (THC). This medication is approved/pending approval in 24 countries including the US, and has licensing agreements with various pharmaceutical giants like Bayer Healthcare and Novartis.

Meanwhile, Epidiolex is the company’s proprietary product candidate currently in an orphan clinical program. With CBD as its active ingredient, the drug is for the treatment of an infantile-onset drug-resistant syndrome of epilepsy called Dravet syndrome.

Aside from these, GW Pharma is also working on other projects, such as the development of another cannabis compound called cannabidivarin (CBDV) for epilepsy.

GW Pharmaceuticals was founded in 1998 by biotech doctors and entrepreneurs Geoffrey Guy and Brian Whittle. It quickly gained support as official investigations in the UK concluded in favor of the potential therapeutic value of cannabis.

Today, the company is being traded in both the NASDAQ Global Market (as GWPH) and London’s Alternative Investment Market (as GWP). Its market cap is pegged at USD 1.65 B, one of the biggest in this Green Rush. Key executives in the company include Dr. Geoffrey Guy, Executive Chairman; Justin D. Gover, CEO; Adam David George, CFO; Christopher John Tovey, COO; and Dr. Stephen Wright, R&D Director.

GW Pharmaceuticals, PLC

Porton Down Science Park
Salisbury, Wiltshire
SP4 0JQ
United Kingdom

Phone: +44 (0) 1980 557000
Fax: +44 (0) 1980 557111
Email: info@gwpharm.com
Website: http://www.gwpharm.com/


Yahoo! Finance: GWPH News

Latest Financial News for GWPH

Here's Why You Should Hold on to IDEXX (IDXX) Stock for Now

Investors continue to be optimistic about IDEXX's (IDXX) performance.

Abbott Forms Alliance With Omada Health for Diabetes Care

Abbott (ABT) collaborates with Omada Health to revolutionize diabetes care by expanding technological access.

This CBD Oil-Making Biotech Has Been Pummeled In 2019 — Here's Why

Investors have pummeled GW stock recently, an analyst said, following recent concerns over prescriptions of its CBD oil, Epidiolex. Data suggest prescriptions slowed in early October.

CHF Solutions System to be Used in JAHVH Study After Final Nod

CHF Solutions' (CHFS) Aquadex system to be used for the outpatient study on heart failure, conducted by James A. Haley Veterans' Hospital and Clinics. The study receives final approval.